Patents by Inventor Anavaj Sakuntabhai

Anavaj Sakuntabhai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
    Patent number: 11872276
    Abstract: The present invention is directed to a Zika virus (ZIKV) chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition. The present invention provides means, in particular polynucleotides, vectors and cells expressing said chimeric polyepitope. The present invention also relates to a composition or a vaccine comprising at least one of said polyepitope, polynucleotide, vector or host cell for use in the prevention of a ZIKV infection in a human subject, or for use in the prevention of ZIKV and dengue virus (DENV) infections in a human subject.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: January 16, 2024
    Assignees: INSTITUT PASTEUR, UNIVERSIDAD EL BOSQUE
    Inventors: Claude Roth, Etienne Simon-Loriere, Anavaj Sakuntabhai, Felix Delgado
  • A NOVEL COMPLEX FORMED BETWEEN THE FLAVIVIRAL NON-STRUCTURAL NS1 PROTEIN AND PLASMA LIPOPROTEINS
    Publication number: 20220341933
    Abstract: The invention concerns methods for early detection, monitoring and prognosis of a flavivirus-induced infection, comprising the detection of a complex formed by the flavivirus non-structural glycoprotein NS1 and plasma lipoprotein particles in a biological anti-NS1 Mab sample during the clinical phase of the infection.
    Type: Application
    Filed: September 25, 2020
    Publication date: October 27, 2022
    Inventors: Marie FLAMAND, Kyu-Ho Paul PARK, Souheyla BENFRID, Carole TAMIETTI, James VOSS, Fasseli COULIBALY, Veasna DUONG, Philippe DUSSART, Anavaj SAKUNTABHAI, Quentin GIAI GIANETTO, Mariette MATONDO, Mariano DELLAROLE, Francois BONTEMS, Felix REY
  • ZIKA VIRUS CHIMERIC POLYEPITOPE COMPRISING NON-STRUCTURAL PROTEINS AND ITS USE IN AN IMMUNOGENIC COMPOSITION
    Publication number: 20220233678
    Abstract: The present invention is directed to a Zika virus (ZIKV) chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition. The present invention provides means, in particular polynucleotides, vectors and cells expressing said chimeric polyepitope. The present invention also relates to a composition or a vaccine comprising at least one of said polyepitope, polynucleotide, vector or host cell for use in the prevention of a ZIKV infection in a human subject, or for use in the prevention of ZIKV and dengue virus (DENV) infections in a human subject.
    Type: Application
    Filed: March 14, 2022
    Publication date: July 28, 2022
    Applicants: INSTITUT PASTEUR, UNIVERSIDAD EL BOSQUE
    Inventors: Claude ROTH, Etienne SIMON-LORIERE, Anavaj SAKUNTABHAI, Felix DELGADO
  • Zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
    Patent number: 11305003
    Abstract: The present invention is directed to a Zika virus (ZIKV) chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition. The present invention provides means, in particular polynucleotides, vectors and cells expressing said chimeric polyepitope. The present invention also relates to a composition or a vaccine comprising at least one of said polyepitope, polynucleotide, vector or host cell for use in the prevention of a ZIKV infection in a human subject, or for use in the prevention of ZIKV and dengue vims (DENV) infections in a human subject.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: April 19, 2022
    Assignees: INSTITUT PASTEUR, UNIVERSIDAD EL BOSQUE
    Inventors: Claude Roth, Etienne Simon-Loriere, Anavaj Sakuntabhai, Felix Delgado
  • Dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
    Patent number: 11034730
    Abstract: The present invention is directed to a dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection. The present invention provides means, in particular polynucleotides, vectors, cells and methods to produce vectors expressing said chimeric polyepitopes, in particular vectors consisting of recombinant measles virus (MV) particles. The present invention also relates to the use of the recombinant MV particles, in particular under the form of a composition or of a vaccine, for the prevention and/or treatment of a dengue virus infection.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: June 15, 2021
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT PASTEUR DU CAMBODGE
    Inventors: Frederic Tangy, Anavaj Sakuntabhai, Etienne Simon-Loriere, Claude Roth, Philippe Buchy
  • A ZIKA VIRUS CHIMERIC POLYEPITOPE COMPRISING NON-STRUCTURAL PROTEINS AND ITS USE IN AN IMMUNOGENIC COMPOSITION
    Publication number: 20200282043
    Abstract: The present invention is directed to a Zika virus (ZIKV) chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition. The present invention provides means, in particular polynucleotides, vectors and cells expressing said chimeric polyepitope. The present invention also relates to a composition or a vaccine comprising at least one of said polyepitope, polynucleotide, vector or host cell for use in the prevention of a ZIKV infection in a human subject, or for use in the prevention of ZIKV and dengue virus (DENV) infections in a human subject.
    Type: Application
    Filed: November 8, 2018
    Publication date: September 10, 2020
    Inventors: Claude ROTH, Etienne SIMON-LORIERE, Anavaj SAKUNTABHAI, Felix DELGADO
  • Large Form Of Human 2',5'-Oligoadenylate Synthetase OAS3 for Preventing or Treating Infection With Positive-Sense Single-Stranded RNA Viruses
    Publication number: 20110189155
    Abstract: Use of the large form of human 2?,5?-Oligoadenylate Synthetase (OAS3) for diagnosis, prevention and treatment of infection with positive-sense single-stranded RNA viruses and for prediction of human genetic susceptibility to positive-sense single-stranded RNA virus-related diseases.
    Type: Application
    Filed: May 20, 2009
    Publication date: August 4, 2011
    Inventors: Anne-Claire Brehin, Anavaj Sakuntabhai, Philippe Despres, Isabelle Casademont, Cécile Julier, Ampaiwan Chuansumrit, Prida Malasit, Sylvie Paulous